Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers

被引:0
|
作者
Wojciech Krzyzanski
Elzbieta Wyska
机构
[1] University at Buffalo,Department of Pharmaceutical Sciences
[2] State University of New York,Department of Pharmacokinetics and Physical Pharmacy
[3] Jagiellonian University,undefined
关键词
Target-mediated drug disposition; Pharmacokinetic model; Receptor binding; Internalization;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study was to apply the target-mediated drug disposition (TMDD) pharmacokinetic (PK) model to describe binding, internalization, and turnover of erythropoietin receptor (EPOR). This model allows one to determine from free drug (C) PK data not only parameters describing linear disposition of EPO such as the elimination rate constant (kel) and volume of distribution (Vc), but also the total receptor concentration (Rtot0), drug–receptor complex (RC) internalization rate constant (kint), as well as synthesis and degradation rate constants (ksyn and kdeg) for the receptor turnover. The previously published data on PK of recombinant EPO (rHuEPO) in humans and the results of EPOR binding studies were used for analysis. The estimated PK parameters were used to simulate time courses of free and bound EPOR after IV administration of clinically relevant rHuEPO doses. The estimates of kel = 0.106 h−1 and Vc = 0.032 l/kg are consistent with reported in the literature values of rHuEPO linear disposition parameters. The determined value of Rtot0 was 66.35 pM and the half-life for EPOR degradation was 8.8 h. Computer simulations showed a very rapid binding phase in the EPOR time profile followed by a decline to a nadir, and a subsequent return to the baseline. The nadir values decreased with increasing doses and resulted in the maximum values of the bound fractions of the total EPOR in the ranges 33–99%. At the baseline conditions, only 3.1% of EPOR were occupied. The saturation of EPOR was correlated with the time C remained above the KD level. In conclusion, the time courses of serum rHuEPO concentrations contain information about internalization and turnover of EPOR. Kinetics of EPOR can be utilized to determine the relationship between the pharmacologic effect and exposure to rHuEPO.
引用
收藏
页码:637 / 645
页数:8
相关论文
共 50 条
  • [1] Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers
    Krzyzanski, Wojciech
    Wyska, Elzbieta
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2008, 377 (4-6) : 637 - 645
  • [2] Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers
    Marzo, A
    Dal Bo, L
    Mazzucchelli, P
    Monti, NC
    Tettamanti, RA
    Crivelli, F
    Uhr, MR
    Ismaili, S
    Giusti, A
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1999, 49 (12): : 992 - 996
  • [3] Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
    Alain Munafo
    Anthony Priestley
    Ivan Nestorov
    Jennifer Visich
    Mark Rogge
    European Journal of Clinical Pharmacology, 2007, 63 : 647 - 656
  • [4] PHARMACOKINETICS AND PHARMACODYNAMICS OF NIFEDIPINE IN HEALTHY-VOLUNTEERS
    KLEINBLOESEM, CH
    VANBRUMMELEN, P
    VANDELINDE, JA
    BREIMER, DD
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1983, 5 (04) : 191 - 191
  • [5] Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers
    Kimura, M
    Umemura, K
    Ikeda, Y
    Kosuge, K
    Mizuno, A
    Nakanomyo, H
    Ohashi, K
    Nakashima, M
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (05) : 583 - 588
  • [6] Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
    Li, Junfeng
    Zhang, Zhaoyun
    Liu, Xiaoxia
    Wang, Yi
    Mao, Fei
    Mao, Junjun
    Lu, Xiaolan
    Jiang, Dongdong
    Wan, Yun
    Lv, Jia-Ying
    Cao, Guoying
    Zhang, Jing
    Zhao, Naiqing
    Atkinson, Mark
    Greiner, Dale L.
    Prud'homme, Gerald J.
    Jiao, Zheng
    Li, Yiming
    Wang, Qinghua
    FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [7] Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers
    Hu, Pei
    Yin, Qi
    Deckert, Fabienne
    Jiang, Ji
    Liu, Dongyang
    Kjems, Lise
    Dole, William P.
    He, Yan-Ling
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (01): : 39 - 49
  • [8] Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
    Munafo, Alain
    Priestley, Anthony
    Nestorov, Ivan
    Visich, Jennifer
    Rogge, Mark
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (07) : 647 - 656
  • [9] PHARMACOKINETICS AND PHARMACODYNAMICS OF GLIPIZIDE IN HEALTHY-VOLUNTEERS
    PENTIKAINEN, PJ
    NEUVONEN, PJ
    PENTTILA, A
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1983, 21 (02) : 98 - 107
  • [10] Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers
    Donaldson, Kirsteen
    Custodio, Joseph M.
    Mann, Grace
    Hunt, Hazel J.
    MUSCLE & NERVE, 2023, 68 : S68 - S68